TTOO News and Press, T2 Biosystems Inc. From 07/11/22

LEXINGTON, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the ...

T2 Biosystems ( NASDAQ: TTOO ) was downgraded by BTIG Research to Neutral from Buy after the company placed its preliminary Q2 revenue numbers below consensus. The SA Quant Rating on TTOO is Strong Sell , which takes into account factors such as growth and profitabi...

T2 Biosystems ( NASDAQ: TTOO ) expects Q2 revenue to be $5.8M to $6.1M, including product revenue of $2.5M to $2.7M and research revenue of $3.3M to $3.4M. Raised $4.6M of net proceeds from the sale of 25.9M shares through the ATM facility during Q2 of 2022. Cash ...

LEXINGTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the quarter ended June 30, 2022. Recent Hig...

LEXINGTON, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to appear on the Benzinga All Access show on Friday, June 17, 2022. Management...

T2 Biosystems (NASDAQ:TTOO) request for an extension until November 1, 2022, to regain compliance with minimum bid price requirement has been granted by the Nasdaq Hearings Panel. During the extension period, the company will continue to actively monitor the stock price while it consider...

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request fo...

T2 Biosystems (NASDAQ:TTOO) on Friday said the U.S. Patent and Trademark Office had issued a patent for methods and systems to rapidly detect tick-borne pathogens, which also covered the company's T2Lyme Panel. TTOO stock +9.7% to $0.23 in morning trade. TTOO said its T2Lyme Panel c...

LEXINGTON, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213 (the ‘213 Patent)...

T2 Biosystems (NASDAQ:TTOO) stock fell May 6, a day after it reported its Q1 results. Q1 revenue rose +4% Y/Y to $7.23M. The company said product revenue declined 17% Y/Y to 3.84M, mainly due to decreased COVID-19 test sales. Meanwhile, contribution revenue grew +47% Y/Y to $3.39M. Net l...